Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, ...

A new study has shed light on the health risks faced by people who stop using weight-loss medications Ozempic or Wegovy.

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

In fact, more and more teens that meet certain weight and health criteria are going on GLP-1s after the FDA’s approval of ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

New data shows that men are still more likely than women to be diagnosed with diabetes in the U.S., rates of the disease have ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

After easing diabetes and weight loss journey for many, the popular medications Ozempic and Wegovy have shown ... Researchers ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

A doctor has explained there are some little-known symptoms and side effects of diabetes that men and women will only see in ...